Switch to:
Also traded in: Denmark, Germany, UK
» Details

Insider Trades

Latest Guru Trades with GNMSF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology  
Compare:OTCPK:NVZMY, OTCPK:UCBJY, NAS:TSRO, NAS:SGEN, OTCPK:GIKLY, NAS:BMRN, NAS:ALKS, NAS:JAZZ, NAS:UTHR, NAS:EXEL, NAS:IONS, NAS:ACAD, NAS:ARIA, NAS:TECH, NAS:ALNY, NAS:GLPG, NAS:ICPT, NAS:RARE, NAS:CBPO, NAS:CLVS » details
Traded in other countries:GEN.Denmark, GE9.Germany, 0MGB.UK,
Genmab A/S is an antibody company focused on cancer. Its first marketed product is Arzerra (ofatumumab); development pipeline incl. daratumumab and two proprietary technology platforms; DuoBody (bispecifics) & HexaBody (effector function enhancement).

Genmab A/S is a biotechnology company that utilizes antibody products. The Company's treatments focus on cancer and other serious illnesses. The Company has a pipeline of drugs in various stages of development and approval. The Company has licensed rights to HuMAb-Mouse, a transgenic mouse technology designed by Medarex. The platform produces high affinity human antibodies. Using the technology also circumvents the need for humanization or genetic engineering which can often drag out drug development. The Company also uses its proprietary UniBody platform. UniBody also binds to one site and produces no immune response. HuMax-CD38 is a drug in development for the treatment of multiple myeloma. The Company also has treatments for asthma (R1671 and R4930), peripheral vascular disease (R1512), hepatitis C (HuMax-HepC), organ transplant rejection (HuMax-TAC), cancer (HuMax-CD32b), and oncology (HuMax-TF). The Company has a myriad of other products in development, pending completion and approval. The Company owns its own manufacturing facilities. Within the facilities, it has the capabilities of producing multiple antibody products simultaneously.

Ratios

vs
industry
vs
history
P/E(ttm) 116.86
GNMSF's P/E(ttm) is ranked lower than
88% of the 277 Companies
in the Global Biotechnology industry.

( Industry Median: 27.33 vs. GNMSF: 116.86 )
Ranked among companies with meaningful P/E(ttm) only.
GNMSF' s P/E(ttm) Range Over the Past 10 Years
Min: 42.72  Med: 88.04 Max: 133.3
Current: 116.86
42.72
133.3
PE(NRI) 116.86
GNMSF's PE(NRI) is ranked lower than
88% of the 250 Companies
in the Global Biotechnology industry.

( Industry Median: 27.67 vs. GNMSF: 116.86 )
Ranked among companies with meaningful PE(NRI) only.
GNMSF' s PE(NRI) Range Over the Past 10 Years
Min: 42.64  Med: 87.82 Max: 181.04
Current: 116.86
42.64
181.04
Price/Owner Earnings (ttm) 175.44
GNMSF's Price/Owner Earnings (ttm) is ranked lower than
86% of the 144 Companies
in the Global Biotechnology industry.

( Industry Median: 29.85 vs. GNMSF: 175.44 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
GNMSF' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 124.69  Med: 293.58 Max: 712.66
Current: 175.44
124.69
712.66
P/B 21.51
GNMSF's P/B is ranked lower than
94% of the 1089 Companies
in the Global Biotechnology industry.

( Industry Median: 3.65 vs. GNMSF: 21.51 )
Ranked among companies with meaningful P/B only.
GNMSF' s P/B Range Over the Past 10 Years
Min: 1.63  Med: 9 Max: 25.04
Current: 21.51
1.63
25.04
P/S 58.90
GNMSF's P/S is ranked lower than
76% of the 846 Companies
in the Global Biotechnology industry.

( Industry Median: 12.69 vs. GNMSF: 58.90 )
Ranked among companies with meaningful P/S only.
GNMSF' s P/S Range Over the Past 10 Years
Min: 3.08  Med: 15.31 Max: 68.87
Current: 58.9
3.08
68.87
PFCF 136.43
GNMSF's PFCF is ranked lower than
87% of the 142 Companies
in the Global Biotechnology industry.

( Industry Median: 23.62 vs. GNMSF: 136.43 )
Ranked among companies with meaningful PFCF only.
GNMSF' s PFCF Range Over the Past 10 Years
Min: 3.77  Med: 109.82 Max: 4518.94
Current: 136.43
3.77
4518.94
POCF 131.40
GNMSF's POCF is ranked lower than
91% of the 200 Companies
in the Global Biotechnology industry.

( Industry Median: 21.57 vs. GNMSF: 131.40 )
Ranked among companies with meaningful POCF only.
GNMSF' s POCF Range Over the Past 10 Years
Min: 3.67  Med: 115.59 Max: 1512.17
Current: 131.4
3.67
1512.17
EV-to-EBIT 107.93
GNMSF's EV-to-EBIT is ranked lower than
92% of the 285 Companies
in the Global Biotechnology industry.

( Industry Median: 18.02 vs. GNMSF: 107.93 )
Ranked among companies with meaningful EV-to-EBIT only.
GNMSF' s EV-to-EBIT Range Over the Past 10 Years
Min: -390.3  Med: 11.7 Max: 1482
Current: 107.93
-390.3
1482
EV-to-EBITDA 107.93
GNMSF's EV-to-EBITDA is ranked lower than
93% of the 309 Companies
in the Global Biotechnology industry.

( Industry Median: 15.42 vs. GNMSF: 107.93 )
Ranked among companies with meaningful EV-to-EBITDA only.
GNMSF' s EV-to-EBITDA Range Over the Past 10 Years
Min: -1007.1  Med: 8.65 Max: 1482
Current: 107.93
-1007.1
1482
Current Ratio 9.89
GNMSF's Current Ratio is ranked higher than
76% of the 949 Companies
in the Global Biotechnology industry.

( Industry Median: 4.17 vs. GNMSF: 9.89 )
Ranked among companies with meaningful Current Ratio only.
GNMSF' s Current Ratio Range Over the Past 10 Years
Min: 1.3  Med: 2.14 Max: 10.33
Current: 9.89
1.3
10.33
Quick Ratio 9.89
GNMSF's Quick Ratio is ranked higher than
77% of the 947 Companies
in the Global Biotechnology industry.

( Industry Median: 3.94 vs. GNMSF: 9.89 )
Ranked among companies with meaningful Quick Ratio only.
GNMSF' s Quick Ratio Range Over the Past 10 Years
Min: 1.3  Med: 2.14 Max: 10.33
Current: 9.89
1.3
10.33

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -5.80
GNMSF's 3-Year Average Share Buyback Ratio is ranked higher than
66% of the 549 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. GNMSF: -5.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
GNMSF' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -19.9  Med: -5.8 Max: -0.2
Current: -5.8
-19.9
-0.2

Valuation & Return

vs
industry
vs
history
Price/Net Cash 24.02
GNMSF's Price/Net Cash is ranked lower than
85% of the 750 Companies
in the Global Biotechnology industry.

( Industry Median: 5.60 vs. GNMSF: 24.02 )
Ranked among companies with meaningful Price/Net Cash only.
GNMSF' s Price/Net Cash Range Over the Past 10 Years
Min: 7.38  Med: 13.99 Max: 75.2
Current: 24.02
7.38
75.2
Price/Net Current Asset Value 22.74
GNMSF's Price/Net Current Asset Value is ranked lower than
88% of the 879 Companies
in the Global Biotechnology industry.

( Industry Median: 5.27 vs. GNMSF: 22.74 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
GNMSF' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.72  Med: 8.92 Max: 24.04
Current: 22.74
1.72
24.04
Price/Tangible Book 22.48
GNMSF's Price/Tangible Book is ranked lower than
92% of the 1004 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. GNMSF: 22.48 )
Ranked among companies with meaningful Price/Tangible Book only.
GNMSF' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.62  Med: 8.25 Max: 22.66
Current: 22.48
1.62
22.66
Price/Projected FCF 28.40
GNMSF's Price/Projected FCF is ranked lower than
89% of the 168 Companies
in the Global Biotechnology industry.

( Industry Median: 3.15 vs. GNMSF: 28.40 )
Ranked among companies with meaningful Price/Projected FCF only.
GNMSF' s Price/Projected FCF Range Over the Past 10 Years
Min: 17.52  Med: 32.12 Max: 440.6
Current: 28.4
17.52
440.6
Price/Median PS Value 3.85
GNMSF's Price/Median PS Value is ranked lower than
92% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. GNMSF: 3.85 )
Ranked among companies with meaningful Price/Median PS Value only.
GNMSF' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.24  Med: 1 Max: 3.51
Current: 3.85
0.24
3.51
Price/Graham Number 10.81
GNMSF's Price/Graham Number is ranked lower than
93% of the 227 Companies
in the Global Biotechnology industry.

( Industry Median: 2.30 vs. GNMSF: 10.81 )
Ranked among companies with meaningful Price/Graham Number only.
GNMSF' s Price/Graham Number Range Over the Past 10 Years
Min: 4.02  Med: 6.72 Max: 10.79
Current: 10.81
4.02
10.79
Earnings Yield (Greenblatt) (%) 0.90
GNMSF's Earnings Yield (Greenblatt) (%) is ranked higher than
78% of the 1192 Companies
in the Global Biotechnology industry.

( Industry Median: -9.50 vs. GNMSF: 0.90 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
GNMSF' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.1  Med: 1.2 Max: 374.9
Current: 0.9
0.1
374.9

More Statistics

Revenue (TTM) (Mil) $217.6
EPS (TTM) $ 1.78
Beta0.28
Short Percentage of Float0.00%
52-Week Range $101.00 - 205.50
Shares Outstanding (Mil)60.15
» More Articles for GNMSF

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Genmab Appoints Judith Klimovsky, MD, as Chief Development Officer Feb 08 2017
Genmab Announces Updated 2016 Financial Guidance Feb 06 2017
Genmab Announces 2016 Net Sales Figures for DARZALEX® (Daratumumab) Jan 24 2017
Genmab Achieves USD 25 Million Sales Milestone in DARZALEX® (daratumumab) Collaboration with... Jan 06 2017
Genmab A/S breached its 50 day moving average in a Bullish Manner : GNMSF-US : January 6, 2017 Jan 06 2017
Genmab Announces Submission of Regulatory Application for Daratumumab in Relapsed/Refractory... Dec 19 2016
Why Genmab (GNMSF) Might Be a Diamond in the Rough Dec 16 2016
Genmab A/S breached its 50 day moving average in a Bullish Manner : GNMSF-US : December 6, 2016 Dec 06 2016
Genmab A/S (GNMSF): Strong Industry, Solid Earnings Estimate Revisions Dec 01 2016
Why Genmab (GNMSF) Could Shock the Market Soon Nov 28 2016
Genmab Announces U.S. FDA Approval of DARZALEX® (daratumumab) for Relapsed Multiple Myeloma and... Nov 21 2016
Genmab A/S :GNMSF-US: Earnings Analysis: Q3, 2016 By the Numbers : November 14, 2016 Nov 14 2016
Genmab A/S breached its 50 day moving average in a Bullish Manner : GNMSF-US : October 20, 2016 Oct 20 2016
Genmab A/S breached its 50 day moving average in a Bearish Manner : GNMSF-US : August 31, 2016 Aug 31 2016
Drug Stocks to Watch for Earnings on Aug 9: MYL, INCY & More Aug 08 2016
Genmab A/S breached its 50 day moving average in a Bearish Manner : GNMSF-US : July 25, 2016 Jul 25 2016
Genmab/Novartis' Arzerra Gets Unfavorable CHMP Opinion Jun 24 2016
Market Rout Hits Genmab While Buy Ratings Signal 20% Rebound Jun 13 2016
Genmab A/S :GNMSF-US: Earnings Analysis: Q1, 2016 By the Numbers May 17 2016
Genmab A/S: Leads amongst peers with strong fundamentals Apr 08 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK